NCT02867033 2026-03-18
ALTITUDES
Centre Oscar Lambret
Phase NA Active not recruiting
Clinical Trials
486 trialsNCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT05435495 2026-03-18
Mechanisms of Resistance to PSMA Radioligand Therapy
University of California, San Francisco
Recruiting
NCT03265496 2026-03-17
CONCORDE
Centre Oscar Lambret
Phase NA Terminated
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01198119 2026-03-16
NBI-CAB
Centre Oscar Lambret
Phase 2 Terminated
NCT06508463 2026-03-16
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT06222580 2026-03-13
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT06348108 2026-03-13
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06408220 2026-03-13
Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
City of Hope Medical Center
Phase NA Recruiting
NCT06523556 2026-03-13
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06572618 2026-03-13
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06784726 2026-03-13
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
NCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07133997 2026-03-13
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07218510 2026-03-13
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT07322341 2026-03-13
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
University of Washington
Phase 2 Not yet recruiting
NCT07468903 2026-03-13
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase NA Not yet recruiting
NCT07468916 2026-03-13
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT03970096 2026-03-12
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT05098210 2026-03-12
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
NCT05960578 2026-03-12
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT07462247 2026-03-12
Establishment of Image Database for Early Upper Gastrointestinal Cancer, Precancerous Lesions, and Precancerous Conditions
Changhai Hospital
Recruiting
NCT00587314 2026-03-11
ablation IN BE
Mayo Clinic
Enrolling by invitation
NCT07017829 2026-03-11
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT07039760 2026-03-11
Asciminib With or Without Sildenafil for Brain Tumors
Washington University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
NCT02780128 2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1 Terminated
NCT06269978 2026-03-10
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT01334021 2026-03-09
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07112053 2026-03-09
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT07181941 2026-03-06
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT07225985 2026-03-06
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 1/2 Not yet recruiting
NCT03941730 2026-03-05
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
NCT04708067 2026-03-05
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05166616 2026-03-05
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05801913 2026-03-05
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT06203912 2026-03-05
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06498973 2026-03-05
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT06575296 2026-03-05
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT05812807 2026-03-04
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06661720 2026-03-04
STRIKE
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06322602 2026-03-03
Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
Mayo Clinic
Phase NA Recruiting
NCT06935344 2026-03-03
PROVE
Catholic University of the Sacred Heart
Recruiting
NCT03150693 2026-03-02
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
NCT06434064 2026-03-02
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting